GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Tax Rate %

Cadence Pharmaceuticals, (FRA:QEW) Tax Rate % : 0.00% (As of Dec. 2013)


View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Cadence Pharmaceuticals,'s Tax Expense for the three months ended in Dec. 2013 was €0.00 Mil. Cadence Pharmaceuticals,'s Pre-Tax Income for the three months ended in Dec. 2013 was €-3.01 Mil. Therefore, Cadence Pharmaceuticals,'s Tax Rate % for the quarter that ended in Dec. 2013 was 0.00%.


Cadence Pharmaceuticals, Tax Rate % Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Tax Rate % Chart

Cadence Pharmaceuticals, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cadence Pharmaceuticals, Quarterly Data
Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cadence Pharmaceuticals, Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Cadence Pharmaceuticals,'s Tax Rate % for the fiscal year that ended in Dec. 2013 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2013 )/Pre-Tax Income (A: Dec. 2013 )
=0/-17.735
=0.00 %

Cadence Pharmaceuticals,'s Tax Rate % for the quarter that ended in Dec. 2013 is calculated as

Tax Rate %=Tax Expense (Q: Dec. 2013 )/Pre-Tax Income (Q: Dec. 2013 )
=0/-3.006
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cadence Pharmaceuticals, Tax Rate % Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadence Pharmaceuticals, (FRA:QEW) Business Description

Traded in Other Exchanges
N/A
Address
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines